Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

An update on genetic frontotemporal dementia

Open access
Greaves, Caroline V., Rohrer, Jonathan D. · 2019 · Journal of Neurology

Abstract

Frontotemporal dementia (FTD) is a highly heritable group of neurodegenerative disorders, with around 30% of patients having a strong family history. The majority of that heritability is accounted for by autosomal dominant mutations in the chromosome 9 open reading frame 72 (C9orf72), progranulin (GRN), and microtubule-associated protein tau (MAPT) genes, with mutations more rarely seen in a number of other genes. This review will discuss the recent updates in the field of genetic FTD. Age at symptom onset in genetic FTD is variable with recently identified genetic modifiers including TMEM106B (in GRN carriers particularly) and a polymorphism at a locus containing two overlapping genes LOC101929163 and C6orf10 (in C9orf72 carriers). Behavioural variant FTD (bvFTD) is the most common diagnosis in each of the genetic groups, although in C9orf72 carriers amyotrophic lateral sclerosis either alone, or with bvFTD, is also common. An atypical neuropsychiatric presentation is also seen in C9orf72 carriers and family members of carriers are at greater risk of psychiatric disorders including schizophrenia and autistic spectrum disorders. Large natural history studies of presymptomatic genetic FTD are now underway both in Europe/Canada (GENFI-the Genetic FTD Initiative) and in the US (ARTFL/LEFFTDS study), collaborating together under the banner of the FTD Prevention Initiative (FPI). These studies are taking forward the validation of cognitive, imaging and fluid biomarkers that aim to robustly measure disease onset, staging and progression in genetic FTD. Grey matter changes on MRI and hypometabolism on FDG-PET are seen at least 10 years before symptom onset with white matter abnormalities seen earlier, but the pattern and exact timing of changes differ between different genetic groups. In contrast, tau PET has yet to show promise in genetic FTD. Three key fluid biomarkers have been identified so far that are likely to be helpful in clinical trials-CSF or blood neurofilament light chain levels (in all groups), CSF or blood progranulin levels (in GRN carriers) and CSF poly(GP) dipeptide repeat protein levels (in C9orf72 carriers). Increased knowledge about genetic FTD has led to more clinical presymptomatic genetic testing but this has not yet been mirrored in the development of either an accepted FTD-specific testing protocol or provision of appropriate psychological support mechanisms for those living through the at-risk phase. This will become even more relevant as disease-modifying therapy trials start in each of the genetic groups over the next few years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00415-019-09363-4

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The landscape of the frontotemporal dementia spectrum disorders. About 70% is sporadic with approximately equal numbers of TDP-43 proteinopathies and tauopathies (including corticobasal degeneration, CBD progressive supranuclear palsy, PSP Pick’s disease, GGT globular glial tauopathy), and a smaller number of FUSopathies (including atypical frontotemporal lobar degeneration with ubiquitin inclusions, aFTLDU). About 30% is genetic with TDP-43 proteinopathies being the commonest cause (mutations in C9orf72 (usually TDP-43 types A or B), GRN (type A), TBK1 (types A or B), VCP (type D), SQSTM1, and TARDBP) then tauopathies (mutations in MAPT), FUSopathies (mutations in FUS) and other proteinopathies (mutations in CHMP2B)
Fig. 1 The landscape of the frontotemporal dementia spectrum disorders. About 70% is sporadic with approximately equal numbers of TDP-43 proteinopathies and tauopathies (including corticobasal degeneration, CBD progressive supranuclear palsy, PSP Pick’s disease, GGT globular glial tauopathy), and a smaller number of FUSopathies (including atypical frontotemporal lobar degeneration with ubiquitin inclusions, aFTLDU). About 30% is genetic with TDP-43 proteinopathies being the commonest cause (mutations in C9orf72 (usually TDP-43 types A or B), GRN (type A), TBK1 (types A or B), VCP (type D), SQSTM1, and TARDBP) then tauopathies (mutations in MAPT), FUSopathies (mutations in FUS) and other proteinopathies (mutations in CHMP2B)CC BY · PubMed Central
Fig. 2 Schematic of fluid, imaging and cognitive biomarker profiles across the lifespan of C9orf72, MAPT and GRN mutation carriers. NfL neurofilament light chain, DTI diffusion tensor imaging, WM white matter, WMH white matter hyperintensities, GM grey matter, EF executive function, VF verbal fluency, M memory; N naming
Fig. 2 Schematic of fluid, imaging and cognitive biomarker profiles across the lifespan of C9orf72, MAPT and GRN mutation carriers. NfL neurofilament light chain, DTI diffusion tensor imaging, WM white matter, WMH white matter hyperintensities, GM grey matter, EF executive function, VF verbal fluency, M memory; N namingCC BY · PubMed Central
Fig. 3 Genetic testing, counselling and support through the timecourse of genetic FTD. There is commonly a period in proximity to symptom onset of FTD where subtle symptoms may be present but diagnostic criteria have not yet been met—this requires careful assessment and discussion
Fig. 3 Genetic testing, counselling and support through the timecourse of genetic FTD. There is commonly a period in proximity to symptom onset of FTD where subtle symptoms may be present but diagnostic criteria have not yet been met—this requires careful assessment and discussionCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 540

Metadata

Authors
Greaves, C. V., & Rohrer, J. D.
Affiliations
UCL Queen Square Institute of Neurology (GB)
Corresponding author
Rohrer, Jonathan D.
Venue
Journal of Neurology
Published
2019-05-22
Volume
266
Issue
8
Pages
2075-2086
ISSN
  • 0012-1037 (ISSN-L)
  • 0340-5354
  • 1432-1459
OpenAlex
W2946423464
Cited by
500
References
91
Citations by year
2026: 55 · 2025: 78 · 2024: 77 · 2023: 65 · 2022: 100 · 2021: 78 · 2020: 42 · 2019: 4
FWCI
7.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • National Institute for Health and Care Research (CL-2012-18-010)
  • Medical Research Council (MR/M023664/1, MR/M008525/1, MR/J009482/1)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
frontotemporal dementia, genetic frontotemporal dementia, C9orf72, progranulin, MAPT, TMEM106B, behavioral variant frontotemporal dementia, amyotrophic lateral sclerosis, presymptomatic genetic testing, genetic modifiers, neurofilament light chain, dipeptide repeat proteins, biomarkers
MeSH terms
C9orf72 Protein, Humans, Membrane Proteins, Mutation, Nerve Tissue Proteins, Biomarkers, Genetic Predisposition to Disease, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An update on genetic frontotemporal dementia. https://app.cochat.ai/papers/10.1007/s00415-019-09363-4
The paper
Greaves, C. V., & Rohrer, J. D. (2019). An update on genetic frontotemporal dementia. Journal of Neurology. https://doi.org/10.1007/s00415-019-09363-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.